This study was undertaken to determine the role of cholecystokinin in pancreatic enzyme secretion stimulated by bombesin and a meal by (a) comparing the pancreatic enzyme output during bombesin infusion and after a meal to output during caerulein infusion and (b) comparing the inhibitory effect of the cholecystokinin-receptor antagonist lorglumide (CR-1409) on The present study was undertaken to determine the role of cholecystokinin in the stimulation of pancreatic enzyme secretion by bombesin and food in the dog by (a) comparing the effects on pancreatic enzyme secretion of similar plasma cholecystokinin concentrations obtained after feeding and after the infusion of bombesin and the synthetic cholecystokininpeptide caerulein and (b) comparing inhibition by the cholecystokinin-receptor antagonist CR-1409 (lorglumide)' 9 on bombesin and food stimulated pancreatic enzyme secretion to that during infusion of caerulein. Since the dogs were equipped with a gastric fistula, which was kept open during the studies to prevent acid entering the duodenum, we were also able to study the effect of the cholecystokinin-receptor antagonist on gastric acid during the infusions of caerulein and bombesin.
Abstract
This study was undertaken to determine the role of cholecystokinin in pancreatic enzyme secretion stimulated by bombesin and a meal by (a) comparing the pancreatic enzyme output during bombesin infusion and after a meal to output during caerulein infusion and (b) comparing the inhibitory effect of the cholecystokinin-receptor antagonist lorglumide (CR-1409) on enzyme output in response to bombesin and food with the response to caerulein. Bombesin (90 pmollkg per h) and caerulein (30 pmollkg per h) were infused into seven dogs in doses giving similar plasma cholecystokinin peak increments as a meal (mean (SEM) 6.8 (0.8), 6-3 (1.2), and 5.7 (0.8) pM, respectively), together with either saline or 2 mg/kg per h of lorglumide. A background infusion of synthetic secretin 20.5 pmollkg per h was given in each experiment. In addition, gastric acid secretion was determined in the experiments with bombesin and caerulein infusion. Pancreatic protein responses to bombesin (1231 (247) mg/h) and food (1430 (220) mg/h) were similar to the responses to caerulein (1249 (201) mg/h). Lorglumide inhibited pancreatic protein output during stimulation with bombesin by 60%, after the meal by 45%, and during caerulein infusion by 68%. Pancreatic bicarbonate output by bombesin, caerulein, and food was inhibited by lorglumide by 28%, 40%, and 38%, respectively. In contrast, lorglumide significantly increased gastric acid secretion from 1.12 to 7-98 mmol/h during bombesin infusion and from 0.52 to 7 .62 mmol/h during caerulein infusion. In 7 The present study was undertaken to determine the role of cholecystokinin in the stimulation of pancreatic enzyme secretion by bombesin and food in the dog by (a) comparing the effects on pancreatic enzyme secretion of similar plasma cholecystokinin concentrations obtained after feeding and after the infusion of bombesin and the synthetic cholecystokininpeptide caerulein and (b) comparing inhibition by the cholecystokinin-receptor antagonist CR-1409 (lorglumide)' 9 on bombesin and food stimulated pancreatic enzyme secretion to that during infusion of caerulein. Since the dogs were equipped with a gastric fistula, which was kept open during the studies to prevent acid entering the duodenum, we were also able to study the effect of the cholecystokinin-receptor antagonist on gastric acid during the infusions of caerulein and bombesin.
Methods
Seven mongrel female dogs, each weighing [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] kg, were fitted with a chronic duodenal fistula as described by Thomas and a gastric fistula using a Thomas-type cannula, modified so that the inner flange was circular rather than oval.'0" The duodenal Thomas pM after the standard test meal, and 6.3 (1 2) pM during caerulein infusion (Fig 1) .
Infusion of bombesin increased pancreatic protein output from 149 (39) to 1231 (247) mg/h (p<0005); the standard test meal increased pancreatic protein secretion from 221 (62) to 1430(220) mg/h (p<0O01), and caerulein infusion increased pancreatic protein secretion from 220 (62) to 1249 (201) mg/h (p<O0OO5). The pancreatic protein output during bombesin infusion and after the test meal was not significantly different from that during infusion of caerulein (Fig 2) . Pancreatic bicarbonate secretion increased from 1.4 (0.4) to 5.7 (1.2) mmol/h (p<0 01) during bombesin infusion, from [2] [3] [4] [5] [6] [7] [8] [9] (0.5) to 11.8 (1.1) mmol/h (p<OO05) after the test meal, and from 2.3 (0.6) to 5 9 (1.5) mmol/h (p<0c05) during caerulein infusion. Pancreatic bicarbonate output after the test meal was significantly greater (p<O05) than during the infusions. Infusion of bombesin increased gastric acid secretion from 0.05 to 1.12 mmol/h (p<005), while caerulein infusion induced a non-significant increase from 0-07 to 0 52 mmol/ h (Fig 3) .
Infusion of lorglumide did not significantly influence basal or stimulated plasma cholecystokinin concentrations (Fig 1) Lorglumide increased gastric acid output during caerulein infusion from 0.52 to 7.62 mmol/h (p<0-05) and during bombesin administration from 1-12 to 7-98 mmol/h (p<005), while the increase in gastric acid output before administration of the stimulants, from 0-08 to 0-58 mmol/h was not significant (Fig 3) . 4 [tmol/kg per h used in the present study.'7 Interestingly, in the study of Konturek et al the higher dose did not provoke a more profound inhibition of mealstimulated pancreatic protein output. 17 The latter finding may indicate that in their studies all cholecystokinin-receptors on the pancreas were blocked by the doses of the cholecystokininreceptor antagonist administered. Doseresponse studies with various doses of cholecystokinin-8 and lorglumide, however, showed that the doses of lorglumide used in the test meal study did not completely abolish the stimulation of pancreatic protein secretion by cholecystokinin.'7 Unfortunately, the study of Konturek et alt7 cannot be compared with ours in more detail since no plasma cholecystokinin concentrations were measured and therefore no attempt could be made to compare the effect ofthe meal with an appropriate dose of cholecystokinin. Furthermore, the study design was different from ours, since increasing doses oflorglumide were infused after the start of the cholecystokinin infusion, while in our study infusion of lorglumide was started one hour before the test meal stimulation. The finding that two recent studies using different designs have shown that the structurally unrelated cholecystokinin-receptor antagonist L-364,718 also inhibited test meal stimulated pancreatic enzyme secretion further supports the part that cholecystokinin plays in the regulation of postprandial pancreatic enzyme secretion.23 24 Since the inhibitory effect of lorglumide on bombesin-stimulated pancreatic protein secretion (60%) was closely similar to that on the enzyme secretion stimulated by caerulein, it is unlikely that, apart from cholecystokinin, other factors contribute to the regulation of bombesinstimulated pancreatic enzyme secretion. This finding is in agreement with the study of Konturek 
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